Fig. 1From: The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach*All patients had BEC ≥ 300 cells/µL, documented high-dose ICS-LABA ≥ 12 months, and pre-BD FVC < 65% predicted. †p < 0.05 for benralizumab 30 mg Q8W vs placebo. ‡p < 0.05 for benralizumab 30 mg Q4W vs placebo. Error bars represent 95% confidence intervals. BD bronchodilator, BEC blood eosinophil count, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid, LABA long-acting β2-agonist, Q4W every 4 weeks, Q8W every 8 weeksChange from baseline FEV1 in the SIROCCO (A) and CALIMA (B) trials * [20, 24]. Back to article page